This is part 1 of a series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.
In March 2021, the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program, in partnership with Pfizer, announced that 10 research projects have been chosen to receive funding to focus on innovative ways to improve biosimilar adoption in the oncology space.
For this 3-part series of Not So Different, The Center for Biosimilars® has chosen projects that relate to improving perception of biosimilars, choice of biosimilars, and payer preferences for biosimilars.
In this first part, we spoke with Claire Saxton, vice president of education at Cancer Support Community, a worldwide patient and family advocacy organization that provides financial support and navigation services. Saxton discussed how her project titled “Frankly Speaking About Cancer: Biosimilars—Researching Oncology Patient and Caregiver Perceptions” will help address the current perception issues surrounding biosimilars.
For more on biosimilar perception, click here.
For more on NCCN’s biosimilar work, click here.